Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:15 AM
Ignite Modification Date:
2025-12-25 @ 4:15 AM
NCT ID:
NCT00654420
Eligibility Criteria:
Inclusion Criteria:
* Participant has locally advanced or metastatic stage IIIB/IV NSCLC that has relapsed after hemotherapy/chemoratiotherapy
* Participant has had at least one chemotherapy regimen for recurrent or metastatic disease
* Participant is 18 years of age or older
* Participant has a performance status of 0-2 on Eastern Cooperative Group (ECOG) scale
* Women of childbearing potential have a negative pregnancy test
Exclusion Criteria:
* Participant has had chemotherapy within 2 weeks or biological therapy (e.g. bevacizumab) within 4 weeks
* Participant has not recovered from adverse events from previous therapy within 4 weeks
* Participant has received EGFR-Tyrosine Kinase Inhibitor (TKI) inhibitor/anti-EGFR mAb therapy
* Participant has received IGF1R-TKI inhibitor/anti-IGF1R mAB therapy
* Participant has had more than 2 systemic chemotherapies for metastatic disease
* Participant has not completed radiotherapy with complete resolution of toxicities at least 2 weeks before starting in the study
* Participant is taking part in another clinical study
* Participant has a primary central nervous system tumor
* Participant abuses drugs or alcohol
* Participant is pregnant or breastfeeding
* Participant is Human Immunodeficiency Virus (HIV) positive
* Participant has a history of hepatitis B or C
* Participant is using growth hormone or growth hormone inhibitors
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00654420
Study Brief:
Protocol Section:
NCT00654420